Akesobio

Akeso, Inc.
康方生物科技（開曼）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

SHARE PURCHASE PURSUANT TO THE 2021 RESTRICTED SHARE UNIT SCHEME

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

Reference is made to the announcement of the Company dated December 7, 2021 (the "**Announcement**") in relation to the adoption of the 2021 Restricted Share Unit Scheme on December 6, 2021 (the "**2021 RSU Scheme**") and the announcements of the Company dated December 13, 14 and 22, 2021 and January 7, 2022 in relation to the share purchase pursuant to the 2021 RSU Scheme (the "**Share Purchase Announcements**"). Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

Since December 10, 2021, the Trustee has purchased a total number of approximately 2,500,000 Shares (the "**Share Purchase**") on the market (including Shares purchased by the Trustee as announced in the Share Purchase Announcements) for the purpose of the 2021 RSU Scheme at a total consideration of Shares purchased (excluding all related expenses, transaction levy, brokerage, tax, duties and levies) of approximately HK$80,000,000 as a long-term equity incentive for employees in the future.

The Share Purchase was funded by the Company's own financial resources other than proceeds from the listing of the Shares on the Main Board of the Stock Exchange.

As at the date of this announcement, no RSUs have been granted to any Selected Participants pursuant to the 2021 RSU Scheme. The Board will determine at its absolute discretion such number of RSUs to be granted to the Selected Participants under the 2021 RSU Scheme with such vesting criteria and conditions as it may deem appropriate.

By Order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, January 31, 2022

As at the date of this announcement, the Board of the Company comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Mr. XIE Ronggang and Dr. ZHOU Yi as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.